Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuCy vs BuFlu Conditioning for Allogeneic HCT
NCT00774280Phase 3Completed
- Sponsor
- Japan Adult Leukemia Study Group
- Start
- May 2002
- Primary completion
- Nov 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fludarabine in leukemia and myelodysplastic syndrome (MDS) (2 arms), sponsored by Japan Adult Leukemia Study Group. Primary endpoint: Related toxicities of two different conditioning regimens at 8 years. Started May 2002; status: completed.
02
Drugs
fludarabine
03
Conditions
leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00774280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774280.